Previous 10 | Next 10 |
ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced six clinical and preclinica...
ROCKVILLE, MD, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will r...
Jazz Pharmaceuticals announces topline data from Phase 3 Xywav trial. MacroGenics reports positive data for flotetuzumab immunotherapy. Merck provides updated positive data for Keytruda in lung cancer. For further details see: Jazz Announces Topline Data, And Other News:...
MacroGenics (MGNX) publishes a report on the role of Flotetuzumab (also known as MGD006) in the immunotherapy of TP53-positive acute myeloid leukemia ((AML)) in a journal of the American Society of Hematology.Flotetuzumab is an investigational, clinical-stage bispecific DA...
ROCKVILLE, MD, Oct. 15, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of...
The first patient has been dosed in a China-based Phase 2/3 study, MAHOGANY, evaluating Zai Lab's (ZLAB) margetuximab, combined with a checkpoint inhibitor, with or without chemo, for the first-line treatment of HER2-positive gastric cancer or gastroesophageal junction cancer.The PD-1 inhibit...
Leap Therapeutics initiates Phase 2a trial for DKN-01. MacroGenics reports progress on MGA012 development. BridgeBio Pharma starts Phase 2 encaleret trial. For further details see: Leap Therapeutics Initiates Trial, And Other News: The Good, Bad And Ugly Of Biopharma
MacroGenics ([[MGNX]]) announces the development of MGC018, an investigational antibody-drug conjugate ((ADC)) targeting B7-H3 for the treatment of solid tumors in a journal of the American Association for Cancer Research. Preclinical studies showed that MGC018 mediated specific in ...
Manuscript describes preclinical development of MGC018 Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD, Sept. 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), ...
MacroGenics (MGNX) announces encouraging preliminary data from a Phase 1/2 clinical trial evaluating flotetuzumab in acute myeloid leukemia ((AML)) patients. The results were just published in the journal Blood.In a subset of patients high poor prognoses and high unmet medical needs, the comp...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.07% on the day to $4.7. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...
SAN FRANCISCO, July 03, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...